Literature DB >> 8223800

Evaluation of growth hormone in thalassaemic boys with failed puberty: spontaneous versus provocative test.

R Chatterjee1, M Katz, T Cox, H Bantock.   

Abstract

Growth hormone (GH) secretion was determined by evaluating ultradian GH profiles for 12 h and GH responses to insulin stimulated hypoglycaemia (ITT) in 28 stunted boys with beta-thalassaemia major aged 15.2-17.4 years, who presented with pubertal failure (FP). Healthy non thalassaemia prepubertal boys (n = 10) aged 7.5-8.8 years, were studied as controls. All patients had normal responses to ITT with peak GH levels > or = 15 mU/l. Basal GH concentrations (mean +/- sem) (1.65 +/- 0.03 mU/l vs 2.58 +/- 0.27 mU/l; P < 0.05) and the stimulated GH responses (peak GH = 15.4 +/- 0.20 mU/l vs 21.08 +/- 0.78 mU/l; P < 0.001) were significantly lower in the patients with failed puberty than in the controls, indicating that the FP patients had diminished GH reserve and secretory capacity. Moreover, all the GH peak parameters including the maximum spontaneous concentrations (MX-GH) and the area under the GH curve (AUC) were significantly lower in the thalassaemic patients than in the controls (MX-GH = 5.2 +/- 0.21 mU/l vs 20.42 +/- 0.14 mU/l; P < 0.001; AUCb = 421.22 +/- 4.31 mU/l vs 712.20 +/- 3.42 mU/l; P < 0.001). These observations suggest that the thalassaemic patients had endogenous neurosecretory GH deficiency (GHND). Priming with sex steroid did not cause any improvement in the spontaneous or stimulated GH secretory patterns in thalassaemic patients. It was noteworthy that in neither the patients nor the control subjects, was there a significant correlation between the maximum stimulated and the MX-GH concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223800     DOI: 10.1007/bf01953984

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  29 in total

1.  Radioreceptor and radioimmunoassay quantitation of human growth hormone in acromegalic serum: overestimation by immunoassay and systematic differences between antisera.

Authors:  A C Herington; L S Jacobs; W H Daughaday
Journal:  J Clin Endocrinol Metab       Date:  1974-08       Impact factor: 5.958

2.  Induction of puberty in patients with beta-thalassemia major.

Authors:  R Chatterjee; M Katz; B Wonke; A V Hoffbrand; D Politis
Journal:  Birth Defects Orig Artic Ser       Date:  1987

3.  The effects of thyrotropin-releasing hormone and luteinizing hormone-releasing hormone on growth hormone release in patients with homozygous beta-thalassaemia.

Authors:  A Masala; T Meloni; D Galisai; S Alagna; P P Rovasio; S Rassu; A F Milia
Journal:  J Clin Endocrinol Metab       Date:  1982-06       Impact factor: 5.958

4.  Do short children secrete insufficient growth hormone?

Authors:  Z Zadik; S A Chalew; S Raiti; A A Kowarski
Journal:  Pediatrics       Date:  1985-09       Impact factor: 7.124

5.  Growth hormone responses to sleep, insulin hypoglycaemia and arginine infusion.

Authors:  P S Ward; D C Savage
Journal:  Horm Res       Date:  1985

6.  Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion.

Authors:  B B Bercu; D Shulman; A W Root; B E Spiliotis
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

7.  Gonadotrophin, thyrotrophin and prolactin reserve in beta thalassaemia.

Authors:  H Landau; I M Spitz; G Cividalli; E A Rachmilewitz
Journal:  Clin Endocrinol (Oxf)       Date:  1978-08       Impact factor: 3.478

8.  Analyses of 24-hour growth hormone profiles in children: relation to growth.

Authors:  K Albertsson-Wikland; S Rosberg
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

9.  Interrelation of the therapeutic effects of growth hormone and testosterone on growth in hypopituitarism.

Authors:  A Aynsley-Green; M Zachmann; A Prader
Journal:  J Pediatr       Date:  1976-12       Impact factor: 4.406

10.  Depressed serum somatomedin activity in beta-thalassemia.

Authors:  P Saenger; E Schwartz; A L Markenson; J H Graziano; L S Levine; M I New; M W Hilgartner
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

View more
  8 in total

1.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 2.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

Review 3.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

Review 4.  Growth of children with beta-thalassemia major.

Authors:  Louis Ck Low
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

5.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

Review 6.  Iron and copper in male reproduction: a double-edged sword.

Authors:  Eva Tvrda; Rohan Peer; Suresh C Sikka; Ashok Agarwal
Journal:  J Assist Reprod Genet       Date:  2014-09-23       Impact factor: 3.412

7.  Circadian growth hormone secretion in short multitransfused prepubertal children with thalassaemia major.

Authors:  G Katzos; F Harsoulis; M Papadopoulou; M Athanasiou; K Sava
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

8.  Thalassaemia and aberrations of growth and puberty.

Authors:  Andreas Kyriakou; Nicos Skordis
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-27       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.